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Diabetic sensory neuropathy 
A B S T R A C T   
Neurons are polarized cells whose fundamental functions are to receive, conduct and transmit signals. In bilateral 
animals, the nervous system is divided into the central (CNS) and peripheral (PNS) nervous system. The main 
function of the PNS is to connect the CNS to the limbs and organs, essentially serving as a relay between the brain 
and spinal cord and the rest of the body. Sensory axons can be up to 3 feet in length. Because of its long-reaching 
and complex structure, the peripheral nervous system (PNS) is exposed and vulnerable to many genetic, meta-
bolic and environmental predispositions. Lipids and lipid intermediates are essential components of nerves. 
About 50 % of the brain dry weight consist of lipids, which makes it the second highest lipid rich tissue after 
adipose tissue. However, the role of lipids in neurological disorders in particular of the peripheral nerves is not 
well understood. This review aims to provide an overview about the role of lipids in the disorders of the PNS.   
1. Introduction 
About 20 % of the medical consultation in adults are because of 
chronic neurologic diseases [82] and the evaluation of sensory distur-
bances are one of the five most common reasons for neurologic exami-
nations [60]. The prevalence of peripheral neuropathy in the general 
population is 2.4 % and increases to an estimated 8 % for those over 55 
years of age [1,54]. 
The PNS consists of several components that include motor, sensory, 
and autonomic neurons with their afferent or efferent axons, myelinat-
ing and non-myelinating Schwann cells, connective tissue components 
(endoneurium, perineurium, epineurium), and blood/lymphatic vessels. 
The cell bodies of sensory neurons are located in the DRGs and are not 
protected by the blood–brain barrier. 
1.1. Lipid composition of neurons 
Mammalian cells comprise thousands of chemically distinct lipids. 
Lipids can be generally classified into eight families: glycer-
ophospholipids, sphingolipids, glycerolipids, sterol lipids, free fatty 
acids, prenol lipids, saccharolipids, and polyketides [25,26]. For most 
lipids, their functions depend on the molecular structure and can be very 
different for the various classes and even for different lipid species 
within the same class [83]. 
To understand the role of lipids in neuronal pathology, it is important 
to look at myelin and neurons as closely connected anatomical and 
functional units. Unfortunately, little is known on the lipid composition 
of neurons and their differences in the individual neuronal 
compartments. 
The dry weight of the neuronal soma contains about 37 % of lipids in 
total, of which the major classes are phospholipids (57.1 %), cholesterol 
(15.4 %) and galactolipids (4.8 %) [13]. Other lipid species that are 
found in soma are ceramide, glucosylceramides or triglycerides (Fig. 1). 
The major phospholipids are PC and PE. Abundant within the group of 
galactolipids are cerebrosides and sulfatides, which are typically found 
in a molar ratio of 2:1. The neuronal soma also contains tetrasialo (GT)-, 
disialo (GD)- and monosialogangliosides (GM). In contrast to soma, 
neurites contain only 15 % of the dry weight as lipids. They have about 
the same relative content of phospholipids (56.4 %) but higher levels of 
cholesterol (22.1 %) and galactolipids (7.7 %). Also the content of 
sphingomyelin and PS is higher in neurites and the ganglioside pattern 
consists entirely of gangliosides GQ1b, GT1b, GD1b, GD1a, and GD3, 
with no monosialogangliosides [13]. Gangliosides are sphingolipids and 
formed from ceramides by the transfer of a glucose or galactose mole-
cule to generate glucosylceramide (GluCer) and galactosylceramide 
(GalCer). These metabolites are then transformed further into complex 
gangliosides and sulfatides respectively (Fig. 1). Typically, gangliosides 
contain an oligosaccharide head structure with one or more sialic acid 
(e.g. N-acetyl-neuraminic acid). They constitute a large family of lipids 
with more than 100 different species, of which GM1, GD1a, GD1b and 
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GT1b account for 96 % of the gangliosides in the human brain [74]. 
Neurites in contrast, consist entirely of GQ1b, GT1b, GD1b, GD1a, and 
GD3, without any monosialogangliosides (GM) present [13]. It was long 
presumed that all axonal membrane lipids are synthesized within the 
cell body and moved by anterograde transport into the axons for axonal 
extension. However, more recent data indicated that axons are able to 
perform at least some aspects of lipid metabolism by themselves [89]. 
1.2. Lipid composition of myelin 
Axons are surrounded by segments of myelin sheaths, which are 
lipid-rich multilamellar stacks of membranes. The main function of 
myelin is to insulate the axon and to cluster sodium channels into the 
nodes of Ranvier to allow for saltatory conduction of action potentials 
[77]. Myelin is formed by oligodendrocytes in the central (CNS) and by 
Schwann cells in the peripheral nervous systems (PNS) of vertebrates. 
The lipid composition of myelin is well investigated and varies signifi-
cantly from neurons and other biological membranes. During the active 
phase of myelination, glia-forming cells generate large amounts of lipids 
in a relatively short period. The most abundant lipid classes in myelin 
are cholesterol, galactosylceramide and ethanolamine plasmalogens 
[62] Together, these three classes comprise for 65 % of the total lipid dry 
weight. For most cellular membranes, is the molar ratio of cholesterol, 
phospholipids and glycosphingolipids about 25:65:10 (mol %) whereas 
the molar ratios in myelin are in the range of 40:40:20 (mol %) [62]. 
Cholesterol is an essential structural lipid and provides stability to 
myelin by regulating both fluidity and permeability of the membrane 
and is required for myelin growth and compaction. Electron microscopy 
analysis of mice lacking cholesterol biosynthesis in Schwann cells, re-
veals severe hypomyelination with stretches of uncompacted myelin 
[55]. 
Galactosylceramides and sulfatides with long chain fatty acid moi-
eties, in particular 24:0 and 24:1 fatty acids, are the most abundant SL’s 
in myelin. The final step in the synthesis of galactosylceramide is carried 
out by the UDP-galactose:ceramide galactosyltransferase (CGalT), 
which transfers UDP-galactose to ceramide [81]. For the synthesis of 
sulfatides, galactosylceramide must be transported to the Golgi where a 
3-O-sulfation to the galactose residue takes place through the cerebro-
side sulfotransferase (CST) [9,86]. However, the inactivation of CGalT in 
myelinating Schwann cells did not result in any obvious alterations [73] 
whereas the inactivation of CGalT in neurons using Nestin-Cre resulted 
in a drastic phenotype. The animals showed progressive dysreflexia and 
motor defects and died within 24 days after birth [39]. Electron mi-
croscopy of peripheral nerves revealed extensive splitting and broad-
ening of the myelin sheaths as well as axonal degeneration. 
Given the abundance of galactosylceramides and their enrichment in 
myelin, it is surprising, that deleting CGalT does not impair myelin 
synthesis. Instead, CGalT-deficient oligodendrocytes partially compen-
sated the loss of galactosylceramide by producing 2-hydroxlyated glu-
cosylceramide, a lipid usually not present in myelin. The additional 
deletion of UDP-glucose ceramide glucosyltransferase (UGCG) in CGalT 
knockout mice deleted all glycosphingolipids in myelin but the dys-
myelinating phenotype of CGalT −/− mice was not aggravated further 
[73]. Glycosphingolipids appear therefore not essential for the synthesis 
of compact myelin per se. Instead, these mice partially compensated the 
loss in glycosphingolipids by increasing the synthesis of 2-hydroxlyated 
sphingomyelin. Generally, more than 50 % of galactosylceramides and 
sulfatides are hydroxylated at the 2-C atom of the N-linked fatty acid. 
This reaction is catalyzed by the fatty acid 2-hydroxylase (FA2H) and 
seems to be important for strengthening the network of interconnecting 
hydrogen bonds [3,23,98]. FA2H-deficient mice that lack 2-hydroxly-
ated glycosphingolipids form normal myelin initially, but the myelin 
sheaths degenerate at older age [98]. In humans, mutations in the FA2H 
gene are clinically associated with gait abnormalities, spastic quad-
riparesis, ataxia, and dystonia. FA2H mutations can also cause a form of 
hereditary spastic paraplegia and leukodystrophy. 
Another distinguishing feature of myelin lipid composition is the 
high amount of ethanolamine plasmalogens. Plasmalogens contain a 
vinyl ether at the sn-1 position and an ester at sn-2 position. The sn-1 
position typically contains saturated C16 (C16:0, C18:0) and mono-
unsaturated C18:1 fatty acids, while the sn-2 position mostly contains 
polyunsaturated fatty acids, specifically arachidonic acid (C22:6) or 
docosahexaenoic acid (C20:4) [53]. Plasmalogens can protect unsatu-
rated membrane lipids against oxidation by singlet oxygen [12] and 
have been shown to terminate oxidative chain reactions by stopping 
further lipid peroxidation [78]. 
2. Peripheral neuropathies 
The pronounced polarity and length of the peripheral axons is most 
Fig. 1. Overview of the sphingolipid metabolism and the metabolic steps that were found to be associated with peripheral neuropathies . (1)HSAN1, (2) Fabry 
Disease, (3) GBS, (4) T2DM, (5) Leukodystrophy with PNP [42], (6) CMT [4]. 
Cer Ceramide; FA fatty acids; TG triglycerides; GalCer Galactosylceramide; GluCer Glucosylceramide; LacCer Lactosylceramide; (dh)SM (dihydro)Sphingomyelin. 
Th. Hornemann                                                                                                                                                                                                                                  
Neuroscience Letters 740 (2021) 135455
3
likely a major reason for their vulnerability. The functionality of axons 
relies on the integrity of their perikaryon and on the connection with 
their peripheral targets (muscle, sensory end-organs, blood vessels, 
glands, etc.) as well as long distance axonal transport and continuous 
support from glial elements [59]. 
Peripheral neuropathies can be categorized into hereditary-, in-
flammatory-, neoplastic-, metabolic- and toxic neuropathies (see 
Table 1). Depending on the affected nerve component, they can be 
axonal, demyelinating, or mixed. However, axonal degeneration is 
predominant and in the majority of cases, followed by a demyelinating 
or mixed form [75]. 
If it comes to relevance of lipids in peripheral neuropathies, mostly 
the sphingolipid metabolism is involved (Fig. 1). Sphingolipids (SL) are 
a class of structurally highly diverse lipids and fundamental components 
of eukaryotic cell membranes. SL de-novo synthesis starts at the endo-
plasmic reticulum (ER) with the formation of a sphingoid base, which is 
the common structural element of all SLs. The sphingoid bases are then 
subsequently N-acylated with a fatty acid of variable length. 
The class of sphingolipids encompasses hundreds of structurally 
different sub-species that are formed by multiple enzymes in a tissue and 
isozyme specific manner [56]. There are numerous sphingolipid species, 
which differ in their head group structure but also in carbon chain 
length, unsaturation and hydroxylation of both the sphingoid base and 
fatty acyl moieties [50]. 
2.1. Fabry disease 
Given the high amount of sphingolipids present in neuronal tissue, it 
is not surprising that impairments in the SL metabolism are frequently 
associated with neuronal defects. Mutations in enzymes that catabolize 
SL cause lysosomal storage diseases (LSDs) including multisystem dis-
orders such Nieman-Pick-Disease type C (NPC), Gaucher, Farbers or Tay- 
Sachs disease [65,76]. However, the neuronal manifestations of LSDs 
affect mostly the CNS rather than the PNS. An exception is Fabry disease 
that affects the PNS. Fabry disease is caused by mutations in the GLA 
gene that encodes for the lysosomal enzyme alpha-galactosidase A 
(aGalA) which degrades the glycosphingolipid globotriaosylceramide in 
the lysosomes. aGalA deficiency therefore leads to an accumulations of 
globotriaosylceramide in cells throughout the body, particularly cells 
lining blood vessels, skin, kidneys, heart and the nervous system. Fabry 
is a multisystem disorder affecting several organs involving potentially 
life-threatening complications such as progressive kidney damage, heart 
attack, and stroke. Characteristic features of Fabry disease are episodes 
of neuropathic pain, particularly in the hands and feet (acropar-
esthesias), angiokeratomas, hypohidrosis; corneal opacity or corneal 
verticillata; gastrointestinal problems, tinnitus and hearing loss. 
GLA gene mutations that result in an absence of alpha-galactosidase 
A activity lead to the classic, severe form of Fabry disease whereas 
mutations that decrease but do not eliminate the enzyme’s activity 
usually cause the milder, late-onset forms typically affecting only heart 
or kidneys. Besides conventional medical treatment intravenously 
administered enzyme replacement therapy (ERT) or oral chaperone 
therapy are current therapeutic options in Fabry. Substrate reduction 
therapy (SRT) by blocking the enzyme glucosylceramide synthase (GCS) 
is currently investigated as an alternative therapy in Fabry and other 
LSDs. 
2.2. Hereditary peripheral neuropathies 
Hereditary peripheral neuropathies can be divided into three major 
subgroups based on their predominant phenotype, such as hereditary 
motor and sensory neuropathies (HMSN or Charcot–Marie–Tooth (CMT) 
disease), hereditary sensory and autonomic (HSAN) and hereditary 
motor neuropathies (HMN). CMT is the most frequent hereditary 
neuromuscular disorder with an estimated cumulative prevalence of 1/ 
2500 but showing a strong variation between populations [54]. The 
initial symptoms typically include a predominantly distal, progressive 
muscle weakness and wasting [32]. CMT1 includes dominantly inheri-
ted forms of demyelinating motor and sensory neuropathies. About 
70–80 % of all CMT1 cases is caused by a duplication of the 17p11.2 
locus containing PMP22, a major myelin protein gene [57]. 
In contrast, hereditary sensory and autonomic neuropathies are 
relatively rare, with an incidence of 1:25,000 [68]. Mutations in the 
sphingolipid degrading enzyme S1P-lyase (SGPL1) were associated with 
CMT [4]. In HSANs, primarily sensory and autonomic neurons are 
affected. The HSAN subtypes can be distinguished by the differential loss 
and/or regeneration of the different nerve fiber populations [43]. 
Axonal loss in both, myelinated and unmyelinated fibers, can be 
observed in HSAN patients with ATL1 [29], RAB7 [36], DNMT1 [6] and 
FAM134B [49] mutations. Generally, unmyelinated fibers seem to be 
more affected in HSANs although in some cases such as in HSAN1 there 
is also slowing of conduction and segmental demyelination suggesting 
defects in myelination and/or the nodal complex [35]. 
HSAN1 is an autosomal and dominantly inherited axonal neuropathy 
with a heterogeneous clinical picture. Patients have prominent sensory 
abnormalities and the neurological phenotype is often complicated by 
severe infections, osteomyelitis, and amputations. Symptoms include 
loss of sensation in the feet, severe sensory loss in the upper and lower 
limbs, dysesthesia, distal muscle weakness, distal lower limb sensory 
loss with ulceration and osteomyelitis. Some individuals develop hear-
ing loss [8,19,45,46,61,71,80]. 
HSAN1 has a variable onset with first symptoms being universally 
sensory and occurring at a median age of 20 years (range 14–54 years) 
[87]. HSAN1 is caused by several missense mutation in the SPTLC1 or 
Table 1 
Peripheral Neuropathies.  
Hereditary peripheral 
neuropathies 








Guillain–Barre syndrome Paraneoplastic neuropathy Diabetic neuropathy Alcohol abuse 












hereditary motor neuropathies 
(HMN) 
Vasculitis POEMS syndrome Uremic neuropathy Alcohol abuse 
Familial amyloid 
neuropathy 





Vitamin deficiencies   
Cryoglobulinemia    
Classification of peripheral neuropathies (adapted from [43]). Peripheral neuropathies related to lipid disorder are shown in bold. POEMS: polyneuropathy, orga-
nomegaly, endocrinopathy, monoclonal gammopathy, skin changes. 
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SPTLC2 gene encoding for two subunits of the 
serine-palmitoyltransferase (SPT). Mutations in the SPTLC1 are termed 
HSAN1A whereas mutation in SPTLC2 are called HSAN1C although 
there is no obvious clinical difference between the two forms. 
SPT catalyzes the first and rate-limiting step in the de-novo synthesis 
of sphingolipids [31,33,34], which starts with the conjugation of 
L-serine and palmitoyl-CoA to form sphinganine [37,85,92,97]. Aside 
from L-serine, the enzyme can also use alanine and glycine as alternative 
substrates. This alternate activity forms a category of atypical 1-deoxy--
sphingolipids (1-deoxySL) that lack the C1-hydroxyl group of canonical 
SL [51,67]. This precludes their conversion into complex SLs (sphingo-
myelins and glycosphingolipids) but also prevents their terminal 
degradation by the S1P-lyase (SGPL1) [96]. 
The conjugation with L-alanine forms 1-deoxysphinganine (1-deox-
ySA), while the use of glycine forms 1-deoxymethylsphinganine (1- 
deoxymethylSA) [67,97]. 
Common to all HSAN1 mutations is the permanent shift in the sub-
strate specificity of SPT from L-serine to L-alanine and glycine, which is 
about 20–30 fold increased compared to wild-type SPT [12,46]. Among 
several variants of unclear significance (VUS), eight missense mutations 
in SPTLC1 and four mutations in SPTLC2 have been conclusively linked 
to HSAN1 [11]. 
Elevated 1-deoxySL levels were confirmed in HSAN1 mutant 
expressing cell lines, primary patient cells (lymphocytes and fibroblasts) 
as well as in a transgenic HSAN1 mouse model [24,28] and in HSAN1 
patient plasma [67]. Plasma 1-deoxySL levels correlate with disease 
severity based on the Charcot-Marie-Tooth Examination Score (CMTES). 
Natural history studies revealed that total 1-deoxySL plasma concen-
trations can vary significantly between individual HSAN1 patients (even 
within families and for the same underlying mutation) but they remain 
constant for the individual patients over time [48]. This indicates that in 
addition to the SPT mutations, also other factors are involved in deter-
mining plasma 1-deoxySL levels. 
1-deoxySL were shown to induce disruption of neuronal cytoskeleton 
structures in cultured neuronal cells and induce dose-dependent 
reduction in neurite length [67]. 
1-deoxySL formation is suppressed at elevated L-serine concentra-
tions, which was successfully demonstrated in several preclinical and 
clinical studies. Oral L-serine supplementation as a therapy in HSAN1 
was first successfully tested in a preclinical study using a transgenic 
HSAN1 mouse model and subsequently confirmed in a single case study 
[5] and a 10-week HSAN1 pilot study with 20 HSAN1 patients [28]. 
L-Serine supplementation significantly reduced plasma 1-deoxySL levels 
in both, mice and humans and resulted in improved nerve function in the 
treated mice [28]. In contrast, mice on an L-alanine enriched diet had 
further increased 1-deoxySL levels, and developed a severe neuropathy 
with earlier onset and pronounced sensory loss [28]. Recently, a 
two-year placebo controlled clinical trial with L-serine was completed 
[27]. Although the primary endpoint of the study was not met, the re-
sults showed a significant improvement in the Charcot-Marie-Tooth 
neuropathy score (v2) with minimal side effects [27]. 
2.3. Guillain–Barre syndrome (GBS) 
A special condition in which sphingolipids are involved is the 
Guillain–Barré syndrome (GBS). This inflammatory neuropathy includes 
autoimmune neuritis as well as neuritis directly related to infections of 
the nerve [94]. It is the most common and most severe acute paralytic 
neuropathy, with about 100 000 people developing the disorder 
worldwide every year. GBS can be divided into acute inflammatory 
demyelinating polyradiculoneuropathy (AIDP), axonal forms such as 
acute motor axonal neuropathy (AMAN) as well as acute motor and 
sensory axonal neuropathy (AMSAN) subgroups. The most common 
form of the disease is AIDP, which presents as progressive motor 
weakness, usually beginning in the legs and advancing proximally. 
Symptoms typically peak within four weeks, and then reach a plateau 
before resolving. More than one-half of the patients experience severe 
pain, and about two-thirds have autonomic symptoms, such as cardiac 
arrhythmias, blood pressure instability, or urinary retention. Nerve 
conduction studies show a slowing, or even possible blockage, of 
conduction. 
GBS is caused by autoantibodies that bind to GM1, GD1a, GT1a, and 
GQ1b gangliosides at the nodes of Ranvier. This activates the comple-
ment system and disrupt sodium-channel clusters and axo-glial junc-
tions, which leads to nerve conduction failure and muscle weakness. 
Several outbreaks of GBS have been reported in relation to C. jejuni 
infections [38]. A prospective case-control study in the UK showed that 
27 (26 %) of 96 patients with GBS had a C. jejuni infection shortly before 
the onset of disease, compared with 2% in household controls and 1% in 
age-matched hospital control [70]. Intravenous immunoglobulin (IVIG) 
and plasma exchange have proven efficacious therapies for GBS in large 
randomized, controlled trials [69]. 
2.4. Diabetic neuropathy 
Because of the rising prevalence of diabetes, diabetic peripheral 
neuropathy (DPN) has become the most frequent form of peripheral 
neuropathies. Earlier studies showed that 66 % of patients with type 1 
diabetes and 59 % of patients with type 2 diabetes developed some form 
of neuropathy [22]. Currently, the prevalence of neuropathy in adult 
diabetic patients is estimated at 50 % [40]. Based on the clinical 
appearance and distribution, DPN can be grouped into symmetric 
sensorimotor polyneuropathy, small-fiber, autonomic or acute motor 
neuropathy. 
Length-dependent sensorimotor peripheral neuropathy is evident in 
8% of the patients at the time of diagnosis [66] but increases in fre-
quency with disease duration from 30 % to 66 % [66], also depending on 
whether the neuropathy is defined by clinical or electrophysiologic 
criteria. 
Generally, the duration and level of hyperglycemia are important 
determinants of diabetes associated complications, including neuropa-
thy [2]. The Diabetes Control and Complications Trial (DCCT) reported 
a 60 percent reduction in neuropathy in intensively treated groups after 
five years but the cumulative incidence of neuropathy (15–21 percent) 
and abnormal nerve conduction (40–52 percent) remained substantial 
[2]. Such findings suggested that neuropathy could develop despite 
intensive control of the glucose level. Thus, risk factors besides hyper-
glycemia are probably also involved in the evolution of DPN. 
In particular dyslipidemia appears to be a relevant factor in DPN 
which might be linked to endothelial dysfunction and oxidative stress in 
the DRGs of sensory neurons [90]. In T1DM, elevated levels of 
low-density lipoprotein (LDL), total cholesterol, and triglycerides have 
been shown to be associated with DPN [87]. In T2DM, low HDL levels 
[18,88] have also been reported to influence the development of DPN. In 
contrast, other studies have not demonstrated an association between 
LDL or HDL and neuropathy [15,16,30]. The influence of triglycerides 
with DPN has been evaluated for T1DM (40) and T2DM [18,79,88,95]. 
For patients with mild to moderate diabetes, a correlation between the 
loss of myelinated fibers and triglyceridemia was observed. This asso-
ciation was independent of disease duration, age and diabetes control 
[93]. Another study demonstrated that lower extremity amputations, 
which are highly associated with neuropathy, were more frequent in 
diabetic subjects with elevated triglyceride levels [14]. Other studies 
showed that obesity is associated with DPN in both T1DM [20,87] and 
T2DM [84,88] and a recent study revealed that the prevalence of DPN 
was higher in obese patients compared to lean controls, even in those 
individuals with normoglycemia [15]. 
Interestingly, plasma 1-deoxySLs levels correlate closely with plasma 
triglycerides [64]. Although metabolically not directly interlinked, it 
appears that 1-deoxySL formation is driven by elevated triglyceride 
levels [91]. Several clinical studies showed that 1-deoxySLs are altered 
in metabolic diseases like the metabolic syndrome and T2DM [10,58,64] 
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and a recent study showed that 1-deoxySLs are long-term predictive 
biomarkers for the incidence of T2DM in an asymptomatic population. 
Even after adjusting for fasting glucose, 1-deoxySLs remained predictive 
for T2DM in a binary regression analysis [58]. 
Given the neurotoxicity of 1-deoxySLs in HSAN1, it is intriguing to 
hypothesize that these neurotoxic lipids are also involved in the etiology 
of the DPN. There is a surprising similarity in the clinical symptoms 
between HSAN1 and diabetic neuropathy [10,21]. DPN patients suffer 
from similar symptoms such as peripheral sensory loss and autonomous 
features, neuropathic pain and slow healing wounds. 
So far, there is no effective therapy available for DPN. Given the 
rising number of individuals with T2DM worldwide, an effective therapy 
for DPN is a globally unmet medical need. It is therefore promising, that 
oral L-serine supplementation in diabetic rats not only effectively sup-
pressed plasma 1-deoxySLs levels but also significantly improved sen-
sory nerve function in these animals, without affecting hyperglycemia or 
triglyceride levels [63]. In addition, 1-deoxySLs might be causally 
involved in the progression of T2DM, as 1-deoxySA impairs β-cell 
function and insulin secretion in vitro [99]. 
2.5. Toxic neuropathies 
Many environmental or nutritional agents and numerous drugs can 
cause a peripheral neuropathy [41,72]. Chronic alcoholism accounts for 
many cases of distal symmetric neuropathy. Also drugs such as amio-
darone or antimicrobial agents such as isonizide and chloroquine, heavy 
metals (e.g., lead, arsenic, mercury) and industrial compounds, 
including n-hexane, acrylamide and organophosphates are common 
causes for toxic neuropathies which mostly lead to primary axonal 
damage [41,72]. 
A special situation is the chemotherapy-induced toxic peripheral 
neuropathy (CIPN) which is a common and dose-limiting side effect for 
various cytostatic drugs. This includes drugs such as bortezomib, plat-
inum derivates, taxanes, and vinca alkaloids [17]. Patients’ symptoms 
include pain, numbness, tingling and burning sensations, and motor 
weakness in the extremities. 
Interestingly, neuropathy symptoms of patients treated with pacli-
taxel are also associated with increased plasma 1-deoxySL formation 
[47]. This was recently confirmed in mice treated with docetaxel which 
showed significantly elevated 1-deoxySLs in dorsal root ganglia (DRG) 
after drug treatment [7]. Earlier studies showed that paclitaxel-induced 
neuropathy is associated with a reduced L-serine supply to dorsal root 
ganglia from the surrounding satellite cells [44]. The intraperitoneal 
administration of L-serine in paclitaxel treated mice improved nerve 
conductance and paclitaxel-induced mechanical allodynia/hyperalgesia 
[44]. Unfortunately, 1-deoxySL levels were not analyzed in these mice. 
3. Conclusions 
Among the different lipid classes, primarily SL seem to be relevant in 
neurological disorders. A special role in this context seem to have 1- 
deoxySL that are formed in an alternative reaction during sphingolipid 
de-novo synthesis. Pathological changes in 1-deoxySL formation are 
conclusively linked to HSAN1 but also appear to be involved in other 
conditions such as the diabetic or chemotherapy induced neuropathy. 
Currently, there is only limited therapeutic options for the treatment of 
peripheral neuropathies. Serine supplementation was demonstrated to 
be effective in lowering 1-deoxySL levels and is applied therapeutically 
in HSAN1. Aside from GBS, IVIG is also used for the treatment of other 
neurological disorders including dermatomyositis, chronic inflamma-
tory demyelinating polyneuropathy (CIDP), multifocal motor neuropa-
thy (MMN), myasthenia gravis and stiff person syndrome [52]. 
Therefore and in the long term, a detailed understanding of the under-
lying pathomechanism(s) and of the relevant neurotoxic factors that 
cause peripheral neuropathies is important to develop more targeted 
and mechanism-based therapies. 
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